Wall Street Zen Upgrades Establishment Labs (NASDAQ:ESTA) to “Buy”

Establishment Labs (NASDAQ:ESTA) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday.

ESTA has been the subject of several other research reports. JPMorgan Chase & Co. boosted their price target on shares of Establishment Labs from $71.00 to $80.00 and gave the company an “overweight” rating in a report on Wednesday, December 17th. BTIG Research raised their price objective on Establishment Labs from $86.00 to $88.00 and gave the stock a “buy” rating in a research note on Tuesday, February 24th. Mizuho lifted their target price on Establishment Labs from $90.00 to $100.00 and gave the stock an “outperform” rating in a report on Wednesday, February 25th. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a research note on Monday, December 29th. Finally, Canaccord Genuity Group increased their price target on Establishment Labs from $85.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $87.00.

Establishment Labs Stock Performance

Shares of NASDAQ:ESTA opened at $70.38 on Friday. The firm’s 50 day simple moving average is $70.89 and its 200 day simple moving average is $59.82. Establishment Labs has a fifty-two week low of $26.56 and a fifty-two week high of $83.31. The company has a market capitalization of $2.06 billion, a price-to-earnings ratio of -40.45 and a beta of 0.91. The company has a debt-to-equity ratio of 10.51, a current ratio of 3.04 and a quick ratio of 2.00.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Tuesday, February 24th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.13. The firm had revenue of $64.62 million during the quarter, compared to analysts’ expectations of $63.80 million. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 201.79%. The business’s revenue for the quarter was up 45.2% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.19) earnings per share. As a group, sell-side analysts forecast that Establishment Labs will post -2.41 earnings per share for the current year.

Institutional Trading of Establishment Labs

A number of large investors have recently added to or reduced their stakes in ESTA. Quarry LP bought a new position in shares of Establishment Labs in the 3rd quarter valued at about $34,000. Kestra Advisory Services LLC bought a new stake in shares of Establishment Labs in the 4th quarter valued at about $47,000. State of Wyoming bought a new stake in shares of Establishment Labs in the 3rd quarter valued at about $71,000. Osaic Holdings Inc. lifted its stake in Establishment Labs by 900.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after purchasing an additional 1,800 shares during the last quarter. Finally, MV Capital Management Inc. acquired a new stake in Establishment Labs in the 4th quarter valued at about $146,000. Institutional investors and hedge funds own 72.91% of the company’s stock.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.